financetom
Business
financetom
/
Business
/
Grupo Aeroportuario del Pacifico Issues $283.8 Million in Bonds
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Grupo Aeroportuario del Pacifico Issues $283.8 Million in Bonds
Sep 6, 2024 1:24 PM

04:08 AM EDT, 09/06/2024 (MT Newswires) -- Grupo Aeroportuario del Pacifico (PAC) said Thursday that it issued about 56.5 million long-term bond certificates in Mexico with a five-year maturity at a nominal value of 100 pesos ($5.02) for a total value of about 5.65 billion pesos.

The company said the order book reached an over-subscription of 1.2 times over the original amount.

The proceeds from the bond issuance will be used to pay down other debt, fulfill committed capital investments, and make commercial investments.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Boom Supersonic XB-1 breaks sound barrier over Mojave Desert
Boom Supersonic XB-1 breaks sound barrier over Mojave Desert
Jan 28, 2025
* Boom Supersonic's XB-1 breaks sound barrier in test flight * XB-1 test flight marks milestone for Boom's commercial airliner plans * Boom Supersonic has 130 orders from major airlines for Overture Jan 28 (Reuters) - About 35,000 feet (10,670 meters) over the Mojave Desert, northwest of Los Angeles, Boom Supersonic's XB-1 became the first privately funded airplane to break...
BRIEF-QMSK Technology Co Ltd Files For U.S. IPO - SEC FILING
BRIEF-QMSK Technology Co Ltd Files For U.S. IPO - SEC FILING
Jan 28, 2025
Jan 28 (Reuters) - QMSK Technology Co Ltd: * QMSK TECHNOLOGY CO LTD: FILES FOR U.S. IPO * QMSK TECHNOLOGY CO., LTD: EXPECT IPO OFFERING PRICE FOR ORDINARY SHARES WILL BE IN RANGE OF $4.00 TO $6.00 PER SHARE * QMSK TECHNOLOGY CO: EXPECT US IPO PRICE FOR ORDINARY SHARES WILL BE IN RANGE OF $4.00 TO $6.00 PER SHARE...
Novo Nordisk's Ozempic Gets FDA Approval for Kidney Disease
Novo Nordisk's Ozempic Gets FDA Approval for Kidney Disease
Jan 28, 2025
02:53 PM EST, 01/28/2025 (MT Newswires) -- Novo Nordisk ( NVO ) said Tuesday the US Food and Drug Administration approved its Ozempic to reduce the risk of kidney failure, worsening kidney disease and death due to cardiovascular disease in adults with Type 2 diabetes and chronic kidney disease. Price: 86.01, Change: -1.50, Percent Change: -1.71 ...
US FDA approves Novo Nordisk's Ozempic to reduce diabetic kidney disease progression
US FDA approves Novo Nordisk's Ozempic to reduce diabetic kidney disease progression
Jan 28, 2025
Jan 28 (Reuters) - Novo Nordisk said on Tuesday the U.S. FDA has approved its blockbuster drug Ozempic to lower the risk of progression of chronic kidney disease and the organ's failure, and death due to heart problems in adults with type 2 diabetes. Ozempic belongs to a class of drugs known as GLP-1 receptor agonists and has the same...
Copyright 2023-2026 - www.financetom.com All Rights Reserved